MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Stock-based compensation
Amortization of operating lease ...
Depreciation and amortization
Net proceeds from issuance of co...
Negative Cash Flow Breakdown
Proceeds from sale of common sto...
Net loss
Deferred revenue, net of deferre...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-13,030
-16,274
-18,899
-19,417
Depreciation and amortization
52
52
54
53
Loss on disposal of fixed assets
-
0
-
-
Stock-based compensation
991
889
1,096
1,096
Amortization of operating lease right-of-use asset
145
138
135
132
Non-cash interest expense
-1
-
-1
-1
Accretion on marketable securities
-129
-131
-142
-145
Prepaid expenses and other current assets
1,061
83
-284
-1,777
Other assets
0
0
9
0
Operating lease liability
-165
-100
-159
-216
Deferred revenue, net of deferred contract acquisition costs
-1,457
-447
-284
-239
Accounts payable and accrued expenses
-53
-243
294
3,201
Net cash used in operating activities
-14,707
-16,200
-17,631
-13,759
Purchases of laboratory and other equipment
0
0
26
60
Sales and maturities of marketable securities
5,600
5,575
6,000
2,000
Purchases of marketable securities
5,600
5,674
5,870
2,034
Net cash used in investing activities
0
-99
104
-94
Proceeds from issuance of common stock and warrants, net of issuance costs
-
8
-
-
Net proceeds from issuance of common stock, including option exercises
3
-
-
-
Proceeds from issuance of common stock-ATMFacility
-
30,637
-
-
Proceeds from sale of common stock under open market sale agreement, net of offering costs
-29,710
-
2,313
27,928
Proceeds from issuance of common stock-Equity Line
-
231
-
-
Net proceeds from sale of common stock under 2019 employee stock purchase plan
-157
-
70
0
Issuance of note payable for insurance policy
0
0
0
0
Net proceeds from option exercises
-
-
7
-
Repayment of notes payable
96
283
278
274
Net cash provided by financing activities
909
-283
2,112
27,654
Net change in cash and cash equivalents
-13,798
-16,582
-15,415
13,801
Cash and cash equivalents at beginning of period
30,789
62,786
62,786
67,131
Cash and cash equivalents at end of period
16,991
30,789
47,371
62,786
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
something is missing
$30,869K
Net proceeds from
issuance of common stock,...
$3K
Net cash provided by
financing activities
$909K
(-38.91%↓ Y/Y)
Canceled cashflow
$29,963K
Net change in cash
and cash...
-$13,798K
(23.96%↑ Y/Y)
Canceled cashflow
$909K
Stock-based compensation
$991K
(8.19%↑ Y/Y)
Amortization of operating
lease right-of-use...
$145K
(12.40%↑ Y/Y)
Depreciation and
amortization
$52K
(30.00%↑ Y/Y)
Proceeds from sale of
common stock under open...
-$29,710K
(-7583.63%↓ Y/Y)
Net proceeds from
sale of common stock...
-$157K
(-197.52%↓ Y/Y)
Repayment of notes payable
$96K
(6.67%↑ Y/Y)
Net cash used in
operating activities
-$14,707K
(21.96%↑ Y/Y)
Canceled cashflow
$1,188K
Net loss
-$13,030K
(13.68%↑ Y/Y)
Deferred revenue, net of
deferred contract...
-$1,457K
(-547.56%↓ Y/Y)
Prepaid expenses and
other current assets
$1,061K
(-45.37%↓ Y/Y)
Operating lease liability
-$165K
(-91.86%↓ Y/Y)
Accretion on marketable
securities
-$129K
(-3.20%↓ Y/Y)
Accounts payable and
accrued expenses
-$53K
(97.81%↑ Y/Y)
Buy us a coffee
Vistagen Therapeutics, Inc. (VTGN)
Vistagen Therapeutics, Inc. (VTGN)